Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice A HiSTORIC Consensus Statement

N Mastacouris, R Tannenbaum, A Strunk, J Koptyev, P Aarts, R Alhusayen, FG Bechara, F Benhadou, V Bettoli, A Brassard, D Brown, SE Choon, P Coutts, DLF da Silva, S Daveluy, RP Dellavalle, V del Marmol, L Emtestam, K Gebauer, R GeorgeEJ Giamarellos-Bourboulis, N Goldfarb, I Hamzavi, PG Hazen, B Horváth, J Hsiao, JR Ingram, GBE Jemec, JS Kirby, MA Lowes, AV Marzano, L Matusiak, HB Naik, MM Okun, HH Oon, LAV Orenstein, SY Paek, JC Pascual, P Fernandez-Peñas, BI Resnik, CJ Sayed, L Thorlacius, HH van der Zee, KR van Straalen, A Garg*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Downloads (Pure)



Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. Identifying validated and feasible measures applicable to the practice setting has the potential to optimize treatment strategies and generate generalizable evidence that may inform treatment guidelines.


To establish consensus on a core set of clinician- and patient-reported outcome measures recommended for use in clinical practice and to establish the appropriate interval within which these measures should be applied.

Evidence Review:

Clinician- and patient-reported HS measures and studies describing their psychometric properties were identified through literature reviews. Identified measures comprised an item reduction survey and subsequent electronic Delphi (e-Delphi) consensus rounds. In each consensus round, a summary of outcome measure components and scoring methods was provided to participants. Experts were provided with feasibility characteristics of clinician measures to aid selection. Consensus was achieved if at least 67% of respondents agreed with use of a measure in clinical practice.


Among HS experts, response rates for item reduction, e-Delphi round 1, and e-Delphi round 2 surveys were 76.4% (42 of 55), 90.5% (38 of 42), and 92.9% (39 of 42), respectively; among patient research partners (PRPs), response rates were 70.8% (17 of 24), 100% (17 of 17), and 82.4% (14 of 17), respectively. The majority of experts across rounds were practicing dermatologists with 18 to 19 years of clinical experience. In the final e-Delphi round, most PRPs were female (12 [85.7%] vs 2 males [11.8%]) and aged 30 to 49 years. In the final e-Delphi round, HS experts and PRPs agreed with the use of the HS Investigator Global Assessment (28 [71.8%]) and HS Quality of Life score (13 [92.9%]), respectively. The most expert-preferred assessment interval in which to apply these measures was 3 months (27 [69.2%]).

Conclusions and Relevance:

An international group of HS experts and PRPs achieved consensus on a core set of HS measures suitable for use in clinical practice. Consistent use of these measures may lead to more accurate assessments of HS disease activity and life outcomes, facilitating shared treatment decision-making in the practice setting.
Original languageEnglish
Pages (from-to)1258-1266
Number of pages9
JournalJAMA Dermatology
Issue number11
Early online date27 Sept 2023
Publication statusPublished - 15 Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 American Medical Association. All rights reserved.


Dive into the research topics of 'Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice A HiSTORIC Consensus Statement'. Together they form a unique fingerprint.

Cite this